Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results - Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 - VIR-5500 received Fast Track designation and achieved proof of concept, with pivo
How this was made
The 30-second read
Why it matters
The disclosed cash runway and Fast Track designation may stabilize the stock, while upcoming Phase 3 data could drive future volatility.
Market read
Fresh earnings and regulatory milestones give traders new data to assess Vir's valuation and risk profile.
What to watch
Potential milestone payments up to $1.74B from Gilead could materially boost valuation if trials succeed.
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Third-quarter net loss narrowed and R&D expense declined substantially from the same period in 2025, while the company reported approximately $901.3 million in cash, cash equivalents and investments and maintained its runway outlook into the second half of 2028. However, the company remained pre-revenue on a total-revenue basis, reported a $96.3 million net loss, and its near-term outlook depends on pending pivotal CHD data and oncology development execution.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | −$188K | – | – |
| License and collaboration revenue, three months ended September 30, 2026GAAP | −$200K | – | – |
| Grant revenue, three months ended September 30, 2026GAAP | 12 | – | – |
| Cost of revenue, three months ended September 30, 2026GAAP | — | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $80.04M | – | – |
| Non-cash stock-based compensation expense in research and development expenses, third quarter of 2026GAAP | $4.4M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $24.43M | – | – |
| Non-cash stock-based compensation expense in selling, general and administrative expenses, third quarter of 2026GAAP | $6M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $104.5M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$104.7M | – | – |
| Change in fair value of equity investments, three months ended September 30, 2026GAAP | −$409K | – | – |
| Interest income, three months ended September 30, 2026GAAP | $9.32M | – | – |
| Other expense, net, three months ended September 30, 2026GAAP | −$651K | – | – |
| Total other income, three months ended September 30, 2026GAAP | $8.26M | – | – |
| Loss before benefit from (provision for) income taxes, three months ended September 30, 2026GAAP | −$96.39M | – | – |
| Benefit from (provision for) income taxes, three months ended September 30, 2026GAAP | $143K | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$96.25M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $ (0.57) | – | – |
| Weighted-average shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 169,275,049 | – | – |
| Cash, cash equivalents and investments, September 30, 2026GAAP | approximately $901.3 million | a decrease of $106.5 million during the third quarter of 2026 | – |
| Cash and cash equivalents, September 30, 2026GAAP | $218.9M | – | – |
| Short-term investments, September 30, 2026GAAP | 235,769 | – | – |
| Long-term investments, September 30, 2026GAAP | 442,932 | – | – |
| Total assets, September 30, 2026GAAP | $1.11B | – | – |
| Total liabilities, September 30, 2026GAAP | 215,819 | – | – |
| Total stockholders' equity, September 30, 2026GAAP | 896,036 | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
into the second half of 2028 outlook
- NoteBased on our current operating plans, the Company continues to expect its cash, cash equivalents and investments to fund operations into the second half of 2028.
- NoteTopline data from the pivotal ECLIPSE 1 trial are expected in the fourth quarter of 2026.
- NoteTopline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.
- NoteThe Company expects multiple pivotal trials to begin in 2027.
What drove it
- The decrease in R&D expenses was primarily driven by a non-recurring $75.0 million milestone expense in the third quarter of 2025 due upon VIR-5525 achieving “first in human dosing.”
- R&D expense also reflected recognition of cost recoveries in connection with the Company’s collaborations with Astellas and Norgine in the third quarter of 2026.
- The R&D decline was partially offset by higher manufacturing costs associated with the Company’s oncology and CHD programs.
- The increase in SG&A expenses was primarily due to higher advisory and legal fees.
- VIR-5500 received FDA Fast Track designation and achieved proof of concept.
Concerns
- Total revenues were $ (188) for the three months ended September 30, 2026.
- The company reported net loss of $ (96,252) for the three months ended September 30, 2026.
- ECLIPSE 1 topline data are expected in the fourth quarter of 2026, while ECLIPSE 2 and ECLIPSE 3 topline data are expected in the first quarter of 2027.
- VIR-5818 requires additional backfill cohorts in a more homogeneous patient population in the monotherapy arm to determine optimal dose and schedule.
- The company identified risks including unexpected safety or efficacy data, unexpected costs or delays, manufacturing-capacity challenges, lower-than-expected enrollment, and difficulties obtaining regulatory approvals.
What to watch
- Topline data from the pivotal ECLIPSE 1 trial expected in the fourth quarter of 2026.
- Expanded Phase 2 SOLSTICE results to be presented at AASLD The Liver Meeting 2026 on November 8.
- Topline data from ECLIPSE 2 and ECLIPSE 3 expected in the first quarter of 2027.
- Multiple VIR-5500 pivotal trials expected to begin in 2027.
- A virtual research investor event planned during the first quarter of 2027 regarding the oncology strategy and preclinical pipeline candidates.
- Potential near-term preclinical milestones of up to $45 million under the Gilead collaboration.
Balance sheet and cash flow
- As of September 30, 2026, the Company had approximately $901.3 million in cash, cash equivalents and investments, representing a decrease of $106.5 million during the third quarter of 2026.
- Cash and cash equivalents were $ 218,866 as of September 30, 2026.
- Short-term investments were 235,769 as of September 30, 2026.
- Long-term investments were 442,932 as of September 30, 2026.
- The Company received $90 million in cash consideration from the Gilead collaboration, including a $65 million upfront payment and a $25 million equity investment at a 30% premium.
Analysis
Vir Biotechnology reported a third-quarter 2026 GAAP net loss of $ (96,252), or $ (0.57) per basic and diluted share, compared with net loss of $ (163,141), or $ (1.17) per share, in the same period in 2025. Total revenues were $ (188), compared with $ 240 a year earlier. The filing did not report product revenue, segment revenue, non-GAAP results, gross margin, or cash-flow measures, consistent with the company’s clinical-stage operating profile.
Operating expenses were $ 104,470, versus $ 173,683 in the prior-year quarter. R&D expense was $ 80,040, compared with $ 151,463, with the company attributing the reduction primarily to a non-recurring $75.0 million VIR-5525 first-in-human dosing milestone expense in the third quarter of 2025 and recognition of cost recoveries related to Astellas and Norgine collaborations in the current quarter. Higher manufacturing costs for oncology and CHD programs partially offset those favorable factors. SG&A expense increased to $ 24,430 from $ 22,231 because of higher advisory and legal fees.
The company ended September 30, 2026 with approximately $901.3 million in cash, cash equivalents and investments, a decrease of $106.5 million during the third quarter of 2026. This amount excludes $90 million in upfront consideration from the Gilead collaboration. Under that agreement, Vir received a $65 million upfront payment and a $25 million equity investment at a 30% premium, and may receive up to $45 million in potential near-term preclinical milestones, up to $1.74 billion in further development, regulatory and commercial milestones, and tiered royalties on net sales. Vir continues to expect cash, cash equivalents and investments to fund operations into the second half of 2028.
The central near-term catalyst is pivotal ECLIPSE 1 topline data, expected in the fourth quarter of 2026. ECLIPSE 2 and ECLIPSE 3 topline data are expected in the first quarter of 2027, with all three trials intended to form a comprehensive global filing package for the CHD regimen. In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation for late-line mCRPC, and the company expects multiple pivotal trials to begin in 2027. VIR-5818 remains in Phase 1 and will add monotherapy backfill cohorts following FDA feedback to determine optimal dose and schedule.
The reported period combines a substantially narrower loss and a stated multiyear funding runway with material development dependency. The R&D decline includes identified non-recurring and collaboration-recovery items, while upcoming value-driving events are clinical readouts rather than commercial financial metrics. Attention is focused on the ECLIPSE 1 data timing, subsequent ECLIPSE 2 and 3 results, VIR-5500 progression into pivotal trials, and execution of the Gilead collaboration.
Management, verbatim
We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology.
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable.
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year.
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
Not in the filing
stated, not guessed- Product revenue
- Revenue by operating segment
- Gross profit
- Gross margin
- Non-GAAP revenue, earnings, operating income, net income, or EPS
- Prior-quarter financial comparisons for the reported income-statement metrics
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt balance
- Share repurchases
- Dividends
- Forward revenue guidance
- Forward operating-expense guidance
- Forward gross-margin guidance
- Forward tax-rate guidance
- Previous-release outlook for comparison
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8‑K provides Vir's Q3 financials, cash balance, R&D spend, and updates on its hepatitis delta and oncology pipelines, plus a new Gilead collaboration.
Ticker impact
Vir Biotechnology filed an 8‑K reporting Q3 2026 results, cash balance of $901M and new Fast Track designation for VIR‑5500.
likely modest pressure as the market prices in the cash runway and upcoming trial data.
The filing provides fresh financial numbers and regulatory milestones that were not previously public, giving traders a basis to adjust positions.
Market effects
Biotech sector may see increased interest in Fast Track programs and cash‑rich companies.
U.S. biotech investors could re‑evaluate exposure ahead of upcoming Phase 3 readouts.
Collaboration with Gilead highlights cross‑border partnership trends in pharma.
Counterpoint
Despite cash strength, the lack of near‑term revenue and reliance on trial outcomes could keep the stock under pressure.
Key entities
- companyVir Biotechnology
Biotech firm reporting Q3 results and pipeline updates.
- companyGilead Sciences
Partner in a $90M collaboration to develop T‑cell engager candidates.
